Structure and biology of tissue factor pathway inhibitor

Thrombosis and Haemostasis

Volumn 86, Issue 4, 2001, Pages 959-972

  Bajaj, M S ^a   Birktoft, J J ^a   Steer, S A ^a   Bajaj, S P ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Factor VIIa; Factor Xa; Kunitz domains; TFPI; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; PEPTIDE; PROTEIN; PROTEINASE; TISSUE FACTOR PATHWAY INHIBITOR;

AMINO TERMINAL SEQUENCE; BIOLOGY; BLOOD CLOTTING; CANCER; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL SURFACE; GENE EXPRESSION; HUMAN; LETHALITY; LUNG INJURY; MOLECULAR RECOGNITION; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEINASE INHIBITION; REGULATORY MECHANISM; REVIEW; SEPSIS; SERUM; SMOOTH MUSCLE FIBER; TISSUE SPECIFICITY; VASCULAR ENDOTHELIUM;

EID: 0034758293     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616518     Document Type: Review

References (177)

1. Tissue factor pathway inhibitor and the current concept of blood coagulation
2. The tissue factor pathway: How it has become a "prima ballerina"
3. New insights into how blood clots: Implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy
4. Measurement of basal levels of factor VIIa in hemophilia A and B patients
5. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
6. The regulation of the factor VII-dependent coagulation pathway: Rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders
7. Activation of human factor VII by activated factors IX and X
8. Tissue factor and haemostasis
9. Isolation and characterization of human factor VII. Activation of factor VII by factor Xa
10. Kinetics of human factor VII activation
11. Initiation of the extrinsic pathway of blood coagulation: Evidence for the tissue factor dependent autoactivation of human coagulation factor VII
12. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism
13. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces
14. Factor XI activation in a revised model of blood coagulation
15. The role of factor XI in coagulation: A matter of revision
16. Thrombin activates factor XI on activated platelets in the absence of factor XII
17. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa
18. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation
19. Biological activities of the contact factors in vivo - Potentiation of hypertension, inflammation and fibrinolysis, and inhibition of cell adhesion
20. Inhibition of factor VIIa/tissue factor-induced coagulation: With particular emphasis upon a factor Xa-dependent mechanism
21. Complex dependent inhibition of factor VIIa by antithrombin and heparin
22. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa
23. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant
24. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Schwartzman reaction
25. A plasma protein that inhibits tissue factor-factor VII activation of factor IX in the presence of factor X
26. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component
27. Regulation of coagulation by a multivalent Kunitz-type inhibitor
28. The extrinsic pathway inhibitor. A regulator of tissue factor dependent blood coagulation
29. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains
30. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor
31. Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor
32. Hemophilia as a defect of the tissue factor pathway of blood coagulation: Effect of factors VIII and IX on factor X activation in a continuous-flow reactor
33. Initiation and regulation of tissue factor dependent blood coagulation
34. The role of tissue factor pathway inhibitor in a revised coagulation cascade
35. Tissue factor pathway inhibitor - A regulator of tissue factor-induced coagulation
36. Tissue factor pathway inhibitor: Clinical deficiency states
37. Tissue factor pathway inhibitor: Potential therapeutic applications
38. Tissue factor pathway inhibitor
39. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant
40. The second Kunitz domain of tissue factor pathway inhibitor: Cloning, structure determination and interaction with factor Xa
41. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
42. Structure of human des (1-45) factor Xa at 2.2 Å resolution
43. X-ray structure of active site-inhibited clotting factor Xa: Implications for drug design and substrate recognition
44. The three dimensional structure of the second Kunitz-like domain of the tissue factor pathway inhibitor
45. Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor: Crystallographic refinement at 1.9 Å resolution
46. Human factor IX and factor IXa
47. Strategies in the design of inhibitors of serine proteases of the coagulation cascade: Factor Xa
48. Alteration of the substrate and inhibitor specificities of blood coagulation factor VIIa: Importance of amino acid residue K192
49. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor-VIIa with Xa-tissue factor pathway inhibitor
50. Directed glycosylation of human coagulation factor X at residue 333. Insight into factor Va-dependent prothrombin catalysis
51. The behavior and significance of slow-binding enzyme inhibitors
52. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor
53. 2+ site in the protease domain of human coagulation factor Xa
54. Inhibitory properties of separate recombinant Kunitz type protease inhibitor domains from tissue factor pathway inhibitor
55. Lipoprotein associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergetic anticoagulant action between LACI and sulfated polysaccharides
56. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: A segment, Gly212-Phe243 is a heparin binding site
57. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity
58. Tissue factor pathway inhibitor: The carboxy-terminus is required for optimal inhibition of factor Xa
59. Kinetics of inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor
60. The effect of leukocyte elastase on tissue factor pathway inhibitor
61. Effect of leukocyte proteinase on tissue factor pathway inhibitor
62. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis
63. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues
64. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues
65. Down-regulation of urine tissue factor pathway inhibitor mRNA by endotoxin and tumor necrosis factor-alpha in vitro and in vivo
66. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma
67. Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells
68. Tissue factor pathway inhibitor production by human mesangial cells in culture
69. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue Factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH
70. Expression of tissue factor pathway inhibitor in human fetal and placental tissues
71. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators
72. Shear stress decreases endothelial cell tissue factor activity by augmenting secretion of tissue factor pathway inhibitor
73. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture
74. Regulation of monocyte tissue factor activity by allogenic and xenogenic endothelial cells
75. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation
76. Expression of tissue factor and factor VIIa/tissue factor inhibitor activity in endotoxin or phorbol ester stimulated U937 monocyte-like cells
77. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors
78. Regulation of tissue factor pathway inhibitor expression in smooth muscle cells
79. Synthesis and expression of tissue factor pathway inhibitor by serum-stimulated fibroblasts, smooth muscle cells and cardiac myocytes
80. Regulation of tissue factor gene
81. Heterogeneity of plasma tissue factor pathway inhibitor
82. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
83. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples
84. Extrinsic coagulation pathway inhibitor and heparin cofactor II during normal and hypertensive pregnancy
85. Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables
86. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives
87. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort
88. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits
89. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor
90. Human Ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor
91. The low density lipoprotein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis
92. Recombinant full-length tissue factor pathway inhibitor fails to bind to the cell surface: Implications for catabolism in vitro and in vivo
93. Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor
94. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein
95. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor
96. Identification of the 1.4 kb and 4.0 kb messages from the lipoprotein-associated coagulation inhibitor and expression of the encoded protein
97. Structure of the human lipoprotein-associated coagulation inhibitor gene. Intron/exon gene organization and localization of the gene to chromosome 2
98. Intron-exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor: The factor Xa dependent inhibitor of the extrinsic pathway of coagulation
99. Revised DNA sequence of exon 1 and 5N flanking region of the human tissue factor pathway inhibitor gene
100. The promoter of the human tissue factor pathway inhibitor gene: Identification of potential regulatory elements
101. GATA-binding transcription factors in hematopoietic cells
102. Cloning of the GATA-binding protein that regulates endothelin-1 gene expression in endothelial cells
103. Role of GATA motifs in tissue factor pathway inhibitor gene expression in malignant cells
104. Tissue factor pathway inhibitor gene disruption
105. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: Impact of the V264M substitution on plasma levels of TFPI
106. No link between the TFPI V264M mutation and venous thromboembolic disease
107. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis
108. A new T287C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association study of the T287C and C399T polymorphisms with coronary artery disease and plasma TFPI levels
109. The 536C→T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis
110. The TFPI 536C→T mutation is not associated with increased risk for venous or arterial thrombosis
111. The C536T transition in the tissue factor pathway inhibitor gene does not contribute to risk of venous thrombosis among carriers of factor V Leiden
112. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
113. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
114. Procoagulant activity expression by macrophages from atheromatous vascular plaques
115. Tissue factor pathway inhibitor expression in atherosclerosis
116. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity
117. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis
118. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels
119. Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages: Relationship to tissue factor induction by cholesterol and oxidized LDL
120. Evolving concepts in the pathogenesis and treatment of arterial thrombosis (Grand rounds)
121. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor
122. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor
123. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions
124. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty
125. Current concepts in coronary thrombolysis
126. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit
127. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor
128. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
129. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs
130. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries
131. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat
132. Experimental acute thrombotic stroke in baboons
133. Expression of tissue factor in hepatic ischemia-reperfusion injury of the rat
134. Tissue factor pathway inhibitor protects the ischemic spinal cord
135. The effect of tissue factor pathway inhibitor on hepatic ischemia reperfusion injury of the rat
136. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction
137. Total and free levels of tissue factor pathway inhibitor: A risk factor in patients with factor V Leiden?
138. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
139. Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor?
140. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis
141. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI 1-161) in experimental venous thrombosis - A comparison with low molecular weight heparin
142. Inhibition of tissue factor pathway during intermittent pneumatic compression: A possible mechanism for antithrombotic effect
143. Increased thromboplastin activity in monocytes of patients with meningococcal infection: Related to an unfavorable prognosis
144. 4b, BP and of inhibitors of tissue factor
145. Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation
146. Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: Low levels of the activated factor X-TFPI complex
147. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases
148. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
149. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli
150. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock
151. The proinflammatory cytokine response to coagulation and endotoxin in whole blood
152. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14
153. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
154. Intravascular coagulation associated with the adult respiratory distress syndrome
155. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome
156. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis
157. Plasma levels of the three endothelial-specific proteins von Willebrand factor, tissue factor pathway inhibitor, and thrombomodulin do not predict the development of acute respiratory distress syndrome
158. Tissue factor as a tumor procoagulant
159. Indices of hyper-coagulation in cancer as compared with those in acute inflammation and acute infarction
160. Immunohistochemical identification of tissue factor in solid tumors
161. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor
162. Elevated TFPI in malignant disease: Relation to cancer type and hypercoagulation
163. Extrinsic coagulation factors and tissue factor pathway inhibitor in end-stage chronic renal failure
164. Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis
165. High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria
166. Tissue factor pathway inhibitor expression in human crescentic glomerulonephritis
167. Mechanism of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complex in the absence of factor Xa
168. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis
169. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis
170. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation
171. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor
172. Partial characterization of novel serine proteinase inhibitors from human umbilical vein endothelial cells
173. Role of tissue factor in embryonic blood vessel development
174. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice
175. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex
176. TFPIβ, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene